If the findings reveal pro-cognitive efficacy of EPO and that this is associated with early prefrontal activity change, this would (1) point to EPO as a candidate compound targeting cognitive dysfunction in somatically healthy patients with mood disorders and (2) highlight prefrontal target engagement as a promising biomarker model for pro-cognitive efficacy. Here, EPO is linked to mood disorder.